Article
Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study.
Cancer chemotherapy and pharmacology - 1 Nov 2023
Ma Yuxiang, Chen Qun, Zhang Yang, Xue Jinhui, Liu Qianwen, Zhao Yuanyuan, Yang Yunpeng, Huang Yan, Fang Wenfeng, Hou Zhiguo, Li Shaorong, Wang Jing, Zhang Li, Zhao Hongyun
Abstract excerpt
PURPOSE: Apatinib combined with gefitinib was proven to benefit advanced EGFR-mutant NSCLC patients in first-line treatment. This study aimed to evaluate the drug-drug interaction of gefitinib and apatinib when coadministered in EGFR-mutated NSCLC patients. METHODS: In this phase 1b, multi-center, open-label, fixed-sequence study, the drug-drug interaction of gefitinib and apatinib was evaluated when...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.